{"product_id":"enoblituzumab-elisa-kit","title":"Enoblituzumab ELISA Kit","description":"\u003cp\u003e\u003cb\u003eSize\u003c\/b\u003e:96T\u003c\/p\u003e\u003cp\u003e\u003cb\u003eApplications\u003c\/b\u003e:ELISA\u003c\/p\u003e\u003cp\u003e\u003cb\u003eAccession\u003c\/b\u003e:Q5ZPR3\u003c\/p\u003e\u003cp\u003e\u003cb\u003eStability and Storage\u003c\/b\u003e:The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eDetection method\u003c\/b\u003e:Colorimetric\u003c\/p\u003e\u003cp\u003e\u003cb\u003eSample type\u003c\/b\u003e:Plasma, Serum\u003c\/p\u003e\u003cp\u003e\u003cb\u003eAssay type\u003c\/b\u003e:Quantitative\u003c\/p\u003e\u003cp\u003e\u003cb\u003eSensitivity\u003c\/b\u003e:0.156 μg\/ml\u003c\/p\u003e\u003cp\u003e\u003cb\u003eRange\u003c\/b\u003e:0.31-5 μg\/mL\u003c\/p\u003e\u003cp\u003e\u003cb\u003eRecovery\u003c\/b\u003e:80-120%\u003c\/p\u003e\u003cp\u003e\u003cb\u003eProperties\u003c\/b\u003e:\u003c\/p\u003e\u003cp\u003e\u003cb\u003eExperimental Procedure\u003c\/b\u003e:\u003c\/p\u003e\u003cp\u003e\u003cb\u003eBackground\u003c\/b\u003e:Enoblituzumab (also referred to as MGA271) is an Fc optimized humanized IgG1 monoclonal antibody that binds to B7-H3 (CD276), a member of the B7 family. This drug was developed by MacroGenics, Inc. that can be potentially used in the treatment of Solid tumors. Enoblituzumab is Fc-engineered with 5 amino acid substitutions to enhance binding to the activating FcγR and decrease binding to the inhibitory FcγR. Pre-clinical studies show that, in human CD16A-bearing transgenic mice, MGA271 exhibited potent antitumor activity in B7-H3–expressing xenograft models of renal cell and bladder carcinoma. To date, approximately 180 patients have received enoblituzumab monotherapy in a phase I study, with good tolerability. To determine the anti-tumor, immunological and biological effects of B7-H3 inhibition in high-risk localized pancreatic cancer, MacroGenics is currently conducting a neoadjuvant and pharmacodynamic phase II study.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eAlternative Names\u003c\/b\u003e:MG-A271, , 1353485-38-7\u003c\/p\u003e\u003cp\u003e\u003cb\u003eShipping\u003c\/b\u003e:2-8 ℃\u003c\/p\u003e\u003cp\u003e\u003cb\u003eNote\u003c\/b\u003e:For Research Use Only.\u003c\/p\u003e","brand":"GeneBio Systems","offers":[{"title":"Default Title","offer_id":48655954509924,"sku":"DV612018","price":932.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0558\/8588\/9636\/files\/no_image_default_image-jpeg_647f7de1-95c3-4a7d-b1c9-cf88200d9c3a.jpg?v=1782808928","url":"https:\/\/www.genebiosystems.com\/en-us\/products\/enoblituzumab-elisa-kit","provider":"GeneBio ","version":"1.0","type":"link"}